Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 6/20 | 0.34 |
| ▸ | GSR | P00390 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6653557 | 0.89 | CPB2 (0.36) | CPB2GSRHDAC1HDAC2HDAC6 | |
| SCHEMBL17369161 | 0.85 | CPB2 (0.39) | CPB2GSRHDAC1HDAC2HDAC6 | |
| SCHEMBL7416589 | 0.85 | CPB2 (0.42) | CPB2GSRHDAC1HDAC2HDAC6 | |
| SCHEMBL1039473 | 0.85 | CPB2 (0.42) | CPB2GSRHDAC1HDAC2HDAC6 | |
| SCHEMBL2211497 | 0.85 | CPB2 (0.42) | CPB2GSRHDAC1HDAC2HDAC6 | |
| Ethylenediamine SCHEMBL17669758 | 0.84 | CPB2 (0.41) | CPB2GSRHDAC1HDAC2HDAC6 | |
| Ethylenediamine SCHEMBL17669759 | 0.84 | CPB2 (0.41) | CPB2GSRHDAC1HDAC2HDAC6 | |
| SCHEMBL6983943 | 0.84 | CPB2 (0.35) | CPB2GSRHDAC1HDAC2HDAC6 | |
| SCHEMBL6987450 | 0.84 | CPB2 (0.35) | CPB2GSRHDAC1HDAC2HDAC6 | |
| SCHEMBL1022347 | 0.80 | CPB2 (0.40) | CPB2GSRHDAC1HDAC2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2007396-B1 | Enfumafungin derivatives as antifungal agents | MERCK SHARP & DOHME (US) | 2013-02-13 | — | — | EP | disclosed |
| US-7863465-B2 | Antifungal agents | MERCK SHARP & DOHME CORP. (US) | 2011-01-04 | — | — | US | disclosed |
| EP-2007396-A1 | ANTIFUNGAL AGENTS | Merck and Co., Inc. (US) | 2008-12-31 | — | — | EP | disclosed |
| US-20080009504-A1 | Antifungal agents | SCYNEXIS, INC. | 2008-01-10 | — | — | US | disclosed |
| WO-2007127012-A1 | ANTIFUNGAL AGENTS | MERCK & CO., INC. (US) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009504-A1 | Antifungal agents | DPM1, MAN2B1, MAN2A1 | CPB2 2422/4885GSR 1773/4885HDAC1 1302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.